Genetically Engineered Mesenchymal Stem Cells as a Proposed Therapeutic for Huntington’s Disease

Huntington’s disease (HD) is an autosomal dominant disorder caused by an expanded CAG trinucleotide repeat that causes a progressive degeneration of neurons in the putamen and caudate nucleus.

Methods

• Huntington's disease (HD) is an autosomal dominant disorder caused by an expanded CAG trinucleotide repeat that causes a progressive degeneration of neurons in the putamen and caudate nucleus.

• Survival and function of striatal neurons is dependent on brain-derived neurotrophic factor (BDNF), and levels of this trophic factor are significantly reduced in HD patients.

• Recently, strategies aimed at BDNF restoration have become leading candidates for the treatment of HD.

• Transplantation of adult stem cells, such as bone marrow-derived mesenchymal stem cells (MSCs), offers considerable therapeutic promise through stimulation of endogenous neuronal growth, decreased neuronal apoptosis, regulation of inflammation, and the secretion of trophic factors. MSCs are readily available, easily expanded in vitro, have immunomodulatory properties, and can be easily engineered to over-produce trophic factors (see Fox et al. 2015 for review).

• The current study tested the pre-clinical safety and efficacy of human MSCs, genetically engineered to produce BDNF, for the treatment of HD.

• Our developmental candidate is allogeneic human MSCs engineered, using a lentiviral vector, to secrete BDNF (MSC/BDNF).

• These proof-of-concept and safety studies were conducted to support HD-CELL, a planned future Phase I clinical trial designed to examine the safety and potential efficacy of MSC/BDNF. The lead in trial, PRE-CELL, is ongoing at UC Davis.

• The current studies focused on the optimal transduction coefficients, the level of BDNF produced by our developmental candidate, the karyotypic stability of the candidate, the safety profile following transplantation in immune-deficient mice, and efficacy following transplantation in the YAC128 and R6/2 transgenic mouse models of HD.

Human Bone Marrow MSCs were isolated from healthy adult bone marrow aspirates.

- Cells are cultured following optimized standard operating procedures in MEM Alpha, 20% fetal bovine serum, 1% L-glutamine, and 1% penicillin/streptomycin.

- MSCs are transduced using a lentivirus containing BDNF under the MNDU3 promoter.

- Transduction is confirmed via q-PCR for viral copy number per cell and protein expression is quantified with ELISA.

- Behavioral and histological outcomes will be measured following bilateral transplantation of 500,000 cells per hemisphere in HD transgenic YAC128 or R6/2 mice.

- Cells will be transplanted into immune-suppressed YAC128 mice at 8.5 months of age and were tested weekly in the open field for 10 minutes to measure spontaneous motor activity and anxiety.

- Six weeks post-transplantation (when the mice are 10 months old), the mice intracranially perfused and their brains removed for histological analysis. Primary histological analysis in the YAC128 was striatal volume.

- R6/2 (120 CAG) mice were transplanted at 7 weeks of age. Half of the mice were intracranially perfused 5 weeks post surgery for histological analysis to examine neurogenesis and half of the animals were used for analysis of survival.

- IVIS data demonstrates that a combination of FK806 (1 mg/kg) and rapamycin (1 mg/kg) delivered via subcutaneous osmotic mini-pumps were able to increase cell retention to levels similar to that observed in immune-deficient mice (21-28 days). YAC128 mice that were not given subcutaneous osmotic mini-pumps with FK806/Rapa did not have detectable numbers of cells after 14 day. Limit of detection is 250,000 cells or approximately 50% of transplant.

Conclusions

- MSCs/BDNF significantly reduced anxiety, a major debilitating symptom in HD, as measured in the open field assay. Importantly, YAC128 mice treated with MSC/BDNF had reduced levels of striatal atrophy in contrast to sham treated mice, as compared to wild type control mice. A significant increase in neurogenesis-like activity was also observed in the substantia nigra in mice receiving transplantations of MSCs/BDNF. These data suggest that MSCs/BDNF could work through mechanisms of increased neurogenesis and striatal neuron survival is a key endpoint of a planned future clinical trial involving the MSC/BDNF.

- MSCs/BDNF treatment also increased the mean lifespan of the R6/2 mice. Based on the efficacy data reported here, we will be performing the definitive safety assessments required to gain FDA approval for the use of human MSC/BDNF cells in a clinical trial.

- This data, in conjunction with previous reports of BDNF or MSC therapy in Huntington’s disease (Gay et al. 2010, Reviewed in Fink et al. 2015), indicate that intrastriatal BDNF delivery, via MSCs, can prevent behavioral manifestations and neuropathological abnormalities in rodent models of the disease.

- Definitive dose-finding, biosafety, biodistribution, and large animal neurotransplantation targeting studies are currently underway to satisfy FDA comments following our successful Pre-IND interaction.

In Vivo Retention of Human MSC

In vitro Characterization of Human MSC/BDNF

Behavioral Analysis

Histological Analysis

Future Direction

All data will be compiled and submitted in an IND package to the FDA.

Acknowledgements

This work was supported by a National Institute of Health National Research Service Award Postdoctoral Fellowship (1F32NS09072-01) (Parks), Graduate Fellowships NSF GRFP 201611600, NSF IGERT 20151046, T5-HELM0355 (Anderson), National Institute of Health Director’s Transformative Research Awards (1R01GM110914-01A1) (Wheeler-Nutt), Duke Foundation (10A), and philanthropic donors from the HD community, including the Roberson Family and TeamJ3.